BTIG Cuts Keryx Biopharmaceuticals (KERX) to Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Keryx Biopharmaceuticals Announces Second Quarter 2015 Financial Results
August 5, 2015 7:01 AM EDTMajority of phosphate binder patients today have access to Auryxia
CHMP recently adopted a positive opinion for Fexeric® (ferric citrate coordination complex) in the EU
Enrollment complete in ongoing Phase 3 label-expansion study for Auryxia
BOSTON, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced its financial results for the second quarter ended June 30, 2015.
"We are making progress on several important milestones across our... More
